Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 272 results found since Jan 2013.
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis
CONCLUSIONS: Though some ESRD patients on HD had local and systemic AEs after first-dose vaccination, the clinical significance of these symptoms was minor. Our study confirmed the safety profile of ChAdOx1 nCoV-19 in HD patients and presented a new viewpoint on vaccine-related AEs. The SCCS analysis did not find an elevated risk of VAT at 1 month following vaccination. Apart from VAT, other vaccine-related AEs, irrespective of local or systemic symptoms, had minor clinical significance on safety issues. Nonetheless, further coordinated, multi-center, or registry-based studies are needed to establish the causality.PMID:360...
Source: Herpes - September 9, 2022 Category: Infectious Diseases Authors: I-Ning Yang Chin-Li Lu Hung-Jen Tang Yu-Chi Kuo Li-Hwa Tsai Kuan Chieh Tu Jhi-Joung Wang Chih-Chiang Chien Source Type: research
Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across three randomized, placebo-controlled trials
Pain. 2022 Aug 19. doi: 10.1097/j.pain.0000000000002760. Online ahead of print.ABSTRACTClinicalTrials.gov: NCT01165177; NCT01165229; NCT01610414.PMID:36066965 | DOI:10.1097/j.pain.0000000000002760
Source: Herpes - September 6, 2022 Category: Infectious Diseases Authors: Joon Hyung Kim Robert Johnson Martina Kovac Anthony L Cunningham Mohamed Amakrane Keith M Sullivan Alemnew F Dagnew Desmond Curran Anne Schuind Source Type: research
What It Really Feels Like to Have Monkeypox
Since the global monkeypox outbreak began in May 2022, more than 22,000 cases have been confirmed in countries around the world. More than 5,000 of those cases have been recorded in the U.S., with many clustered in hotspots including New York and California. The virus, which often results in a blister-like rash and spreads through close contact, has so far predominantly affected men who have sex with men.
Even as cases tick up and monkeypox gains public attention, however, it can still be difficult to find information about testing, treatment, and vaccines. Many people who fear they are at risk or infected are left to seek...
Source: TIME: Health - August 1, 2022 Category: Consumer Health News Authors: Jamie Ducharme, Angela Haupt and Jeffrey Kluger Tags: Uncategorized healthscienceclimate monkeypox Source Type: news
STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
CDC Endorses Novavax COVID-19 Shot for Adults
U.S. adults who haven’t gotten any COVID-19 shots yet should consider a new option from Novavax—a more traditional kind of vaccine, health officials said Tuesday.
Regulators authorized the nation’s first so-called protein vaccine against COVID-19 last week, but the final hurdle was a recommendation from the Centers for Disease Control and Prevention.
“If you have been waiting for a COVID-19 vaccine built on a different technology than those previously available, now is the time to join the millions of Americans who have been vaccinated,” Dr. Rochelle Walensky, CDC’s director, said in a s...
Source: TIME: Health - July 20, 2022 Category: Consumer Health News Authors: Lauran Neergaard / AP Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news
Zoster sine herpete following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient
IDCases. 2022 Jul 13;29:e01563. doi: 10.1016/j.idcr.2022.e01563. eCollection 2022.ABSTRACTAs a result of the COVID-19 pandemic, mRNA vaccination has become widespread. Recently, it has been suggested that instances of herpes zoster increase following mRNA COVID-19 vaccination. Herein, we describe the first case of zoster sine herpete (ZSH) after mRNA vaccination for COVID-19. A 60-year-old Japanese immunocompetent man presented with fever, fatigue, headache, cervical pain, and lumbar pain, which developed after receiving a second dose of BNT162b2 mRNA COVID-19 vaccination. Whereas most symptoms improved with symptomatic tr...
Source: Herpes - July 20, 2022 Category: Infectious Diseases Authors: Ryutaro Tanizaki Yayoi Miyamatsu Source Type: research
Formulation Optimization and Evaluation of Nanocochleate Gel of Famciclovir for the Treatment of Herpes Zoster
CONCLUSION: A novel nanocochleate gel of Famciclovir was successfully developed for the treatment of infections associated with Herpes Zoster with sustained release action.PMID:35733311 | DOI:10.2174/1872210516666220622115553
Source: Herpes - June 23, 2022 Category: Infectious Diseases Authors: Rahul Sharma Ashwini Deshpande Abhishek Kanugo Source Type: research
A Fourth COVID-19 Vaccine, From Novovax, Passed a Key Stage in the Authorization Process
American adults who haven’t yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot.
Next, the FDA must decide whether to authorize the protein vaccine made by latecomer Novavax as the nation’s fourth coronavirus shot for adults. It’s made with more conventional technology than today’s dominant Pfizer and Moderna shots and the lesser-used Johnson & Johnson option.
Novavax shots are already available in Australia, Canada, parts of Europe and multiple other countries, either for initial va...
Source: TIME: Health - June 8, 2022 Category: Consumer Health News Authors: LAURAN NEERGAARD / AP Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news
FDA Advisers Back a New COVID-19 Vaccine, Made By Novavax
American adults who haven’t yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot.
Next, the FDA must decide whether to authorize the vaccine made by latecomer Novavax, a protein vaccine that’s made with a more conventional technology than today’s U.S. options.
Novavax shots are already used in Australia, Canada, parts of Europe and dozens of other countries. But U.S. clearance is a key hurdle for the Maryland-based company.
FDA’s vaccine chief Dr. Peter Marks said another choice in the U....
Source: TIME: Health - June 7, 2022 Category: Consumer Health News Authors: Lauran Neergaard / AP Tags: Uncategorized COVID-19 wire Source Type: news
COVID-19 mRNA vaccine in pregnancy: Results of the Swiss COVI-PREG registry, an observational prospective cohort study
Lancet Reg Health Eur. 2022 May 29;18:100410. doi: 10.1016/j.lanepe.2022.100410. eCollection 2022 Jul.ABSTRACTBACKGROUND: Pregnant individuals with coronavirus disease 2019 (COVID-19) are at increased risk of severe disease, prematurity, and stillbirth. In March 2021, vaccination for at risk pregnant women was recommended in Switzerland, expanding this to all pregnant women in May 2021. Our aim was to assess the safety of mRNA COVID-19 vaccines in pregnancy.METHODS: This multicentre prospective cohort study describes early adverse events and perinatal outcomes in pregnant women who received at least one dose of mRNA vaccin...
Source: Herpes - June 2, 2022 Category: Infectious Diseases Authors: Guillaume Favre Emeline Maisonneuve L éo Pomar Ursula Winterfeld Charlotte Daire Bego ña Martinez de Tejada Dominique Delecraz Sonia Campelo Mirjam Moser Monya Todesco-Bernasconi Stefanie Sturm Irene H ösli C écile Monod Brigitte Frey Tirri Stylianos Source Type: research
